Exploring & exploiting our 'other self' - does the microbiota hold the key to the future therapy in Crohn's?
Best Pract Res Clin Gastroenterol
; 28(3): 399-409, 2014 Jun.
Article
em En
| MEDLINE
| ID: mdl-24913380
ABSTRACT
Inflammatory bowel diseases (IBD) with its two major forms Crohn's disease (CD) and ulcerative colitis (UC) are chronic relapsing disorders leading to inflammation of the gastrointestinal tract. Although the precise aetiology of IBD remains unclear, several factors are believed to contribute to disease pathogenesis. Among these, the role of the intestinal microbiota has become more and more appreciated. Evidence from experimental and clinical studies strongly suggests that chronic intestinal inflammation results from a dysregulated immune response towards components of the microbiota in genetically susceptible hosts. The growing perception of the microbiota as a major driver of disease pathogenesis raises the question, if the intestinal microbiota can be used as a therapeutic target in CD. Based on what we know about host microbiota interactions in health and disease, the objective of this review is to address the question if the microbiota holds the key to the future therapy in CD.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Crohn
/
Probióticos
/
Microbiota
Limite:
Humans
Idioma:
En
Revista:
Best Pract Res Clin Gastroenterol
Assunto da revista:
GASTROENTEROLOGIA
Ano de publicação:
2014
Tipo de documento:
Article